The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
Completed · Phase 4 · NCT04400318
Conditions: Asthma
At a glance
- Research payments reported, 2025
- $25,250
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 109
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab (drug), Placebo (drug)
- Dates
- Started 2020-06-20; completion 2023-08-21
- Results posted
- Yes
Primary Objective: • To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: * To evaluate the effect of dupilumab at Week 24 on bronchodynamics, hyperinflation, airway resistance, airway wall thickness, ventilation defects and mucus plugging derived from high-resolution computed tomography (HRCT) scans, patient-reported outcomes, FeNO and spirometry. * To evaluate safety of dupilumab
From ClinicalTrials.gov, last updated 2025-09-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $25,250 in research payments for this study in 2025 (55 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $25,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.